8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.97 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€89.14M
Enterprise Value€501.49M
Total Cash (Recent Filing)€65.78M
Total Debt (Recent Filing)€1.07M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding53,330,242
10 Day Avg. Volume268
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA near-zero debt-to-equity ratio and a meaningful equity base provide durable solvency protection for an R&D-intensive biotech. This reduces bankruptcy risk and gives management time and optionality to advance clinical programs or raise capital without immediate refinancing pressure.
Focused Pipeline / Lead CandidateConcentrated development around resomelagon (AP1189) gives a clear strategic focus and scale benefits in expertise and trial design. Success in one core indication (eg, rheumatoid arthritis) could create platform value across inflammation indications, supporting long-term commercial potential.
Improving Cash Burn TrendA reduction in operating cash burn and positive TTM free cash flow growth, even from negative levels, signals better cost control and program prioritization. If sustained, this trend extends runway and reduces the frequency and size of future financing needs.
Bears Say
No Revenue / Pre-commercialThe absence of product revenue means the company remains fully dependent on financing and development milestones. Without commercial sales, long-term viability hinges on clinical success, partner deals, or continued capital raises, making cash and execution risks structural.
Large And Persistent Cash BurnSustained multi-year negative operating and free cash flows indicate ongoing funding needs. Persistent cash burn forces recurrent capital raises or dilution unless offset by revenue or major cost reductions, constraining strategic flexibility and shareholder value over the medium term.
Deep Losses & Negative Returns On EquityVery large net losses and strongly negative ROE reflect structural unprofitability; if sustained, they erode equity and limit ability to fund growth internally. Long-term shareholder value depends on reversing losses through successful commercialization or accretive partnerships.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.97 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €89.14M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 26 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -€0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.044.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.789%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―